Answers are grounded in this paper and cite their sources.
Retrospective cohort study evaluates long-term mortality and adverse events in melanoma patients with stomatitis, suggesting serious implications.
e21600 Background: Immune checkpoint inhibitors (ICIs) have revolutionized treatment for advanced malignant melanoma, but immune-related adverse events (irAEs) such as stomatitis may impact long-term outcomes. The association between stomatitis and subsequent morbidity, including mortality and systemic irAEs, remains underexplored. To evaluate the long-term effects of stomatitis on mortality and other adverse outcomes in melanoma patients receiving ICIs. Methods: Retrospective cohort study using the TriNetX federated database (deprecated COVID-19 Research Network, 88 healthcare organizations). Patients aged ≥18 years with malignant melanoma (ICD-10-CM C43) receiving ICIs (pembrolizumab, nivolumab, or ipilimumab) were divided into cohorts with (n = 1,719) and without (n = 22,228) stomatitis (ICD-10-CM K12). Propensity score matching (PSM) balanced cohorts on demographics, BMI, ECOG score, and comorbidities, yielding 1,708 patients per group. Exposures included-Stomatitis during ICI therapy. Main Outcomes and Measures--Primary outcome: all-cause mortality. Secondary outcomes: respiratory diseases, dysphagia, malaise/fatigue, trismus, fever, circulatory/respiratory symptoms, endocrine/metabolic diseases, circulatory diseases, and digestive diseases. Analyses included risk ratios (RRs), odds ratios (ORs), hazard ratios (HRs) from Kaplan-Meier survival, and mean instances, starting 1 day post-index event (first ICI administration). Results: After PSM, the stomatitis cohort had a higher mortality risk (37.3% vs 31.4%; RR, 0.842 [95% CI, 0.765-0.926]; HR, 0.829 [95% CI, 0.737-0.933]; P = 0.002 for log-rank). Respiratory diseases were more common (53.3% vs 43.3%; RR, 0.813 [95% CI, 0.721-0.917]; P = 0.001; HR, 0.711 [95% CI, 0.600-0.842]; P < 0.001). Dysphagia instances were higher (mean 2.913 vs 2.121; P = 0.023), though risk was borderline (11.2% vs 9.1%; RR, 0.806 [95% CI, 0.648-1.003]; P = 0.053). Circulatory/respiratory symptoms (49.2% vs 42.3%; RR, 0.860 [95% CI, 0.758-0.975]; P = 0.020) and circulatory diseases (59.5% vs 51.5%; RR, 0.866 [95% CI, 0.757-0.990]; P = 0.041; HR, 0.690 [95% CI, 0.562-0.847]; P < 0.001) were elevated in the stomatitis group. No significant differences for malaise/fatigue, trismus, fever, endocrine, or digestive diseases. Conclusions: Stomatitis during ICI therapy for melanoma is associated with increased long-term mortality and select irAEs, particularly respiratory and circulatory complications. These findings suggest stomatitis may signal broader immune dysregulation, warranting closer monitoring.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: